Compare Coursera Inc (COUR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Neurocrine Biosciences Inc — how do they compare? Coursera Inc trades at $5.28 (market cap $1.35B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Neurocrine Biosciences Inc is far larger — about 10.8× Coursera Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and Neurocrine Biosciences Inc for 23 Days on average.
| COUR | NBIX | |
|---|---|---|
Market Cap | $1.35B | $14.60B |
Volume | 5,442,629 | 1,075,694 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $185.50 |
52-Week Low | $4.64 | $123.10 |
Typical Hold Time | 47 Days | 23 Days |
Enterprise Value | $606.18M | $14.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.27, up 2.93% with a bearish technical signal despite recent earnings beats. Revenue growth is solid (2025: $758M, 2026: $885M projected) but profitability remains negative with a -15.39% net margin. Analyst consensus is bullish with a $7.40 price target (52.94% buy ratings), while institutional activity shows mixed positioning amid Project Helix AI platform developments.
The stock offers upside potential from AI-driven growth and margin improvements, but faces execution risks on profitability and integration costs. High RSI near 82 suggests overbought conditions, while persistent net losses and competitive pressures in edtech warrant caution for near-term volatility.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
